BREAKING NEWS

US Supreme Court rules for Teva over multiple sclerosis drug patent

WASHINGTON - The US Supreme Court on Tuesday ruled for Teva Pharmaceutical Industries Ltd in its fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug, by sending the case back to a lower court for further review.
On a 7-2 vote, the justices said that the US Court of Appeals for the Federal Circuit had not used the correct approach in analyzing whether the patent in question, due to expire in September 2015, was valid.
Subscribe for our daily newsletter
Subscribe for our daily newsletter

By subscribing I accept the terms of use

Read all Tweets >